https://promentispharma.com/2014/promentis-pharmaceuticals-raises-nearly-3-million-in-series-b-financing/2017-03-24T11:53:45-05:00https://www.milwaukeemag.com/2016/01/27/mind-matters-mental-health-cover-story/#new_tab2017-03-03T16:48:30-06:00http://www.xconomy.com/wisconsin/2015/10/16/marquettes-new-seed-fund-underscores-entrepreneurship-push/#new_tab2017-03-03T16:50:35-06:00http://www.xconomy.com/wisconsin/2015/02/12/promentis-turns-to-montana-researchers-to-boost-neuro-drug-tech/#new_tab2017-03-03T16:52:32-06:00https://www.biztimes.com/2014/general-news/promentis-raises-nearly-3-million/#new_tab2017-03-03T16:59:16-06:00http://www.bizjournals.com/milwaukee/news/2014/01/16/promentis-pharmaceuticals-raises-29m.html#new_tab2017-03-03T17:00:13-06:00https://www.biocentury.com/bc-week-review/financial-news/completed-offerings/2014-01-27/promentis-pharmaceuticals-completes#new_tab2017-03-03T18:47:07-06:00http://archive.jsonline.com/business/promentis-awarded-grant-to-develop-schizophrenia-drugs-19700nb-171171571.html#new_tab2017-03-03T18:49:39-06:00http://archive.jsonline.com/business/promentis-pharmaceuticals-receives-funding-from-michael-j-fox-foundation-dn6k10r-167332255.html2017-03-03T18:50:56-06:00http://medcitynews.com/2010/02/schizophrenia-drugmaker-promentis-raises-17-million-2/?rf=1#new_tab2017-03-03T18:52:50-06:00http://www.marquette.edu/magazine/recent.php?subaction=showfull&id=1232042099&archive=#new_tab2017-03-03T18:55:18-06:00https://promentispharma.com/2012/promentis-pharmaceuticals-inc-awarded-1800000-phase-ii-sbir-grant-to-develop-more-effective-drugs-for-the-treatment-of-schizophrenia/2017-03-24T11:54:52-05:00https://promentispharma.com/2012/michael-j-fox-foundation-awards-299000-to-promentis-pharmaceuticals-inc-to-develop-parkinsons-disease-drugs/2017-03-24T11:55:30-05:00http://archive.jsonline.com/business/promentis-pharmaceuticals-raises-29-million-in-venture-capital-b99185768z1-240573471.html#new_tab2017-03-13T12:49:59-05:00http://www.bizjournals.com/milwaukee/news/2013/08/07/sen-baldwin-sees-her-1st-bill.html#new_tab2017-03-13T12:54:39-05:00https://promentispharma.com/2017/promentis-pharmaceuticals-inc-announces-26m-series-c-financing-and-elects-four-new-board-members-2/2017-03-29T18:10:58-05:00https://promentispharma.com/2017/promentis-pharmaceuticals-commences-phase-1-study-for-sxc-2023-targeting-neuropsychiatric-disorders/2017-11-19T18:41:39-06:00https://promentispharma.com/2018/promentis-pharmaceuticals-to-present-at-society-for-neuroscience-meeting-oct-2018/2018-10-28T23:08:06-05:00https://promentispharma.com/2018/promentis-pharmaceuticals-announces-successful-completion-of-phase-1-studies-for-sxc-2023-targeting-novel-glutamatergic-mechanism/2018-11-15T23:00:23-06:00https://promentispharma.com/2018/promentis-pharmaceuticals-to-present-at-the-57th-annual-american-college-of-neuropsychopharmacology-acnp-meeting/2018-12-05T09:55:44-06:00https://promentispharma.com/2019/promentis-pharmaceuticals-announces-commencement-of-phase-2-studies-for-sxc-2023-targeting-novel-glutamatergic-mechanism/2019-01-16T16:51:11-06:00https://promentispharma.com/2019/promentis-pharmaceuticals-to-present-at-the-10th-anniversary-cns-summit/2019-10-31T20:09:06-05:00https://promentispharma.com/2019/promentis-pharmaceuticals-announces-positive-results-for-phase-2a-study-of-sxc-2023-targeting-novel-glutamatergic-mechanism-and-completion-of-enrollment-for-phase-2-trichotillomania-study/2019-10-31T16:37:57-05:00https://promentispharma.com/2020/promentis-pharmaceuticals-to-present-at-the-11th-anniversary-cns-summit/2020-11-07T14:46:50-06:00